美国FDA的抗病毒药物咨询委员会日前经投票决定支持批准Gilead Sciences公司的Truvada(tenofovir disoproxil fumarate/emtricitabine)用于降低未被感染成人感染HIV-1的风险。经过投票,FDA咨询委员会最终以19赞成、3票反对的投票结果支持男同性恋者接触前使用本品以预防艾滋病(PrEP)。另一项19 The FDA’s antiviral advisory board recently voted to support the approval of Gilead Sciences’s Truvada (tenofovir disoproxil fumarate / emtricitabine) to reduce the risk of HIV-1 infection in uninfected adults. After the vote, the FDA Advisory Committee ended the vote with 19 votes in favor and 3 votes against the gay men before using this product to prevent AIDS (PrEP). Another one